文章核心观点 - 文章作者Terry Chrisomalis运营名为Biotech Analysis Central的医药服务 提供针对多家制药公司的深度分析 [1] - 作者此前曾撰写关于Xencor的文章 重点关注其plamotamab在非霍奇金淋巴瘤的数据及类风湿性关节炎项目的进展 [2] 作者及服务介绍 - Biotech Analysis Central服务在Seeking Alpha平台的订阅价格为每月49美元 年度计划可享受3350%的折扣 年费为399美元 [1] - 该投资分析小组拥有一个包含600多篇生物技术投资文章的资料库 [2] - 服务内容包括一个包含10多只中小市值股票的投资组合模型及每只股票的深度分析 实时聊天以及一系列分析和新闻报告 [2] 披露信息 - 作者声明未持有任何提及公司的股票、期权或类似衍生品头寸 且在接下来72小时内无建立此类头寸的计划 [3] - 文章内容仅代表作者个人观点 作者除Seeking Alpha的报酬外未获得其他补偿 与任何提及公司无业务关系 [3]

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed an amended and restated preliminary short form base shelf prospectus (the “Prospectus”) to provide the Company with the flexibility to take advantage of financing opportunities and favourable market con ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?My Buy call on Intellia Therapeutics, Inc. (NASDAQ: NTLA ) stock made in a Seeking Alpha post published last month—August 15th, to be precise—has already paid off. Shares have been soaring in value thisThe group is ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?My Buy call on Intellia Therapeutics, Inc. (NASDAQ: NTLA ) stock made in a Seeking Alpha post published last month—August 15th, to be precise—has already paid off. Shares have been soaring in value thisThe group is ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Despite a faltering jobs market , rising auto and student loan defaults , concerning CRE delinquencies in the Office and Multifamily spaces, and a collapsing housing sector in many regions of the country like Austin, Las Vegas, Oakland, ...

公司财务行动 - 公司于2025年9月19日以20比1的比例进行反向股票分割 旨在通过减少流通股数量提高每股价格[1] - 当前股价为1.52美元 日交易区间为1.46美元至1.585美元 年波动区间为0.131美元至3.29美元[5] - 公司市值约为1.926亿美元 日交易量为4,701,878股[5] 产品研发进展 - 公司正在推进新型双靶点融合蛋白telitacicept的三期临床开发[2] - 将在中国开展的三期研究中展示针对成人全身型重症肌无力的48周临床数据[2] - 该研究由在香港和上海证券交易所上市的合作伙伴荣昌生物制药有限公司赞助[2] 学术会议参与 - 将于2025年10月29日10:50在旧金山美国神经肌肉与电诊断医学协会年会上公布临床数据[3] - 报告标题为"Telitacicept在全身型重症肌无力患者中的疗效和安全性：三期研究结果"[3] - 公司还将参加Stifel 2025虚拟免疫与炎症论坛 包括炉边谈话和一对一投资者会议[4] 企业合作与交流 - 公司计划于2025年9月15日通过网站直播方式进行炉边谈话[4] - 通过投资者会议展现对投资者关系和信息透明度的承诺[4] - 临床数据发布被视为展示临床研究进展的关键节点[3]

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Last week, Seeking Alpha posted some takes on potential buyouts in the biotech/biopharma sector. Thursday morning, Roche ( OTCQX:RHHBY ) announced it was acquiring 89bio, Inc ( ETNB ) in a deal that could reach $3.5 billion, which inclu ...

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets):   2025   2024  Revenue $ 48,867,753  $ 58,590,949  (Loss) Income Before Income Tax $ (1,896,010 ) $ 476,447  Net (Loss) Income $ (1,048,154 ) $ 483,481  Basic Earnings per Share of Common Stock $ (1.17 ) $ .54 Diluted Earnings per Share of Common Stock $ (1.17 ) $ .54 Weighted Average  Number of Shares Outstanding For Basic Earnings Per Share 894,416 894,416  Weighted Average. ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The last time I covered ProKidney (NASDAQ: PROK ), the Winston-Salem, North Carolina based biotech, for Seeking Alpha, it was July, and its share price was skyrocketing, jumping from $0.6, to >$4.5 overnight, after ...

PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that Raghu Rao, Interim Chief Executive Officer of Sonnet, will present on Thursday, September 25, 2025 at 9:40 AM PT at the MedInvest Biotech & Pharma Conference being held in Palo Alto, California. In addition to the presentation, management will be avail ...